SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is trending as renewed military strikes in the Middle East and Iranian missile activity shatter previous diplomatic de-escalation narratives, reigniting fears of supply disruptions. The community is actively debating whether these geopolitical escalations signal a sustained move toward higher oil prices or if the asset remains subject to manipulative trading and temporary 'peace' headlines.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a tight consolidation range as investors prepare for upcoming earnings that will serve as a crucial test for its AI growth narrative. The community is actively debating the stock's long-term valuation versus the company's operational scaling, with intense focus on whether enterprise adoption and revenue growth can sustain a rebound from recent market pressure.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp is trending as investors monitor ongoing rare earth supply chain developments, with the community actively debating the firm's strategic positioning in the sector and potential future project milestones. Sentiment remains divided between those focused on long-term geopolitical value and others expressing frustration over recent price volatility and communication delays.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Investors are closely tracking TG Therapeutics as market speculation intensifies around potential acquisition interest and the anticipation of upcoming quarterly earnings results. The community remains focused on the company's Briumvi product growth, potential pipeline expansion, and the expectation of long-term value despite ongoing sector volatility.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is trending as investors focus on its pipeline pivot and oncology strategy, with recent bullish momentum fueled by a collaboration with Janux Therapeutics and positive Phase 3 results for mezigdomide. Community sentiment remains fixated on the company's ability to navigate the upcoming patent cliff through strategic acquisitions and pipeline expansion, while traders monitor key breakout levels following recent earnings and analyst upgrades.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano is trending as investors debate the impact of potential regulatory developments like the Clarity Act against a backdrop of prolonged price consolidation and heavy whale accumulation. Community sentiment remains polarized between long-term holders pointing to network upgrades and contrarians highlighting lagging adoption and declining market rankings.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is capturing significant investor attention as the community actively debates its dividend payout consistency compared to similar income ETFs, while many use market pullbacks as opportunities to add to their positions. Investors are heavily focused on the fund's monthly cash flow potential and its ability to act as a defensive, income-generating asset during periods of market volatility.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is currently seeing high investor engagement following the official regulatory clearance and upcoming closure of its SkyWater Technology acquisition, a strategic move designed to bolster the company's domestic manufacturing capabilities and supply chain. Market participants are actively debating the long-term potential of this vertical integration against near-term concerns regarding shareholder dilution and the broader volatility currently impacting high-growth quantum stocks.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing significant market interest following a landmark agreement with the U.S. administration to invest heavily in domestic manufacturing and offer discounted pricing in exchange for a three-year tariff exemption. Investors are actively discussing the implications of this major policy deal on the company's long-term profitability and its upcoming shift to a NYSE listing as the firm continues to prioritize its oncology pipeline and strategic growth initiatives.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is facing downward pressure as investors weigh cooling geopolitical tensions following a tentative U.S.-Iran peace framework against the company's strong contract backlog and debt reduction progress. While the community is actively debating the reliability of the peace deal and its impact on oil supply, sentiment remains divided between those expecting long-term offshore demand to drive a turnaround and those concerned about share dilution and technical resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes OKYO Pharma (OKYO) a New Buy Stock

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) has earned an average recommendation of 'Hold' from the five analysts that are presently covering the firm, MarketBeat.com reports...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 272,194 shares, an increase of 31.9% from the March 31st total of 206,345 shares. Based on...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 435,430...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler

Piper Sandler raised OKYO Pharma to a "strong-buy" rating in a report on Friday...

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited - Ordinary Shares - New

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info